By Richard Jefferys Impressive results from two efficacy trials of a long-acting form of the integrase inhibitor cabotegravir (CAB LA) have boosted prospects for long-acting HIV pre-exposure prophylaxis (PrEP).1,2 In both cases, CAB LA proved superior to oral Truvada PrEP…
By Abraham Johnson The announcement that HIV Prevention Trials Network (HPTN) had two successful studies on long-acting technologies (LAT) to prevent HIV — HPTN 083 and 084 — came with much excitement. Populations most impacted by HIV could possibly have…
By Annette Gaudino and Suraj Madoori Let’s Define Terraforming Terraforming — or “earth-shaping” — the transformation of an alien planet into one where humans can live, is probably most familiar to science-fiction fans and Minecraft players. Terraforming is more intensive…
By Bryn Gay, Joelle Dountio Ofimboudem, and Kenly Sikwese* Meaningful and equitable community engagement is essential to ensuring that long-acting technologies (LATs) clinical research is conducted in ways that are safe, ethical, appropriate, and responsive to community priorities and needs.1…
By Susan Swindells* and Mark Harrington This issue of TAGline explores the exciting opportunities and challenges that come with the development of long-acting formulations for the prevention and treatment of infectious diseases. For many years to date, patients and providers…
How the Trump administration’s anti-immigrant stance threatens human rights, public health, and the lives of people living with TB By Erica Lessem and Suraj Madoori Perhaps the most recognizable symbol of the current presidential administration and the campaign that led…